ReviewHNO2009
[Menière's disease : evidence and controversies].
Review in HNO, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).BMJ (Clinical research ed.) · 2016Trial
- Lermoyez Syndrome: A Systematic Review and Narrative Synthesis of Reported Cases.Audiology research · 2025Review
- Recent surgical options for vestibular vertigo.GMS current topics in otorhinolaryngology, head and neck surgery · 2017Review
- Effect of standard-dose Betahistine on endolymphatic hydrops: an MRI pilot study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2013Article
- Perspectives in vestibular diagnostics and therapy.GMS current topics in otorhinolaryngology, head and neck surgery · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Menière's disease is recognized as the idiopathic form of recurrent inner ear disease with the trias of hearing loss, tinnitus and vertigo with aural fullness and Menière's syndrome as the non-idiopathic form. Subentities with unknown pathogenesis are Lermoyez' s syndrome and Tumarkin crises. A common pathogenetic factor is the disturbance of endolymphatic and perilymphatic osmotic and hydrostatic pressure due to defined etiologies or to idiopathic attacks. Etiologies of Menière's syndrome can be pathologic middle ear pressure, anomalies of the vestibular and cochlear aqueducts, round window topography, patency of the ductus peruniens and the utriculo-endolymphatic valve. Indications for treatment are assessed according to the AAO-HNS guidelines and the neurotological function tests and dizziness inventories. Betahistine is recommended as first choice medical treatment as on-label or high dosage administration. In case of medical treatment failure and if hearing is worth saving, endolymphatic shunt surgery (ELS) is the first choice. If deafferentiation of the labyrinth is needed vestibular neurectomy (VE) should be performed. Local gentamicine administration has good long-term results but macula function can often recover and hearing is often deteriorated. Future aspects for the treatment are new experimental results with gene transfer to vestibular hair cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.